{"id":43142,"date":"2020-02-20T13:56:52","date_gmt":"2020-02-20T11:56:52","guid":{"rendered":"https:\/\/newserver.fyb.de\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/"},"modified":"2020-02-20T13:56:52","modified_gmt":"2020-02-20T11:56:52","slug":"secondary-bridgepoint-acquires-majority-stake-in-pharmazell","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/","title":{"rendered":"Secondary: Bridgepoint acquires majority stake in PharmaZell"},"content":{"rendered":"<p>Munich \u2014 Inter\u00adna\u00adtio\u00adnal private equity inves\u00adtor <strong>Bridge\u00adpoint<\/strong> acqui\u00adres a majo\u00adrity stake in <strong>Phar\u00adma\u00adZell<\/strong> from <strong>DPE Deut\u00adsche Private Equity <\/strong>and<strong> Maxburg Capi\u00adtal Part\u00adners<\/strong>. The parties have agreed not to disc\u00adlose the purchase price.<\/p>\n<p>Phar\u00adma\u00adZell is a leading inde\u00adpen\u00addent manu\u00adfac\u00adtu\u00adrer of Active Phar\u00admaceu\u00adti\u00adcal Ingre\u00addi\u00adents (API) in the highly stable and specia\u00adli\u00adzed API market. There, the company has a diver\u00adsi\u00adfied port\u00adfo\u00adlio of more than 70 active ingre\u00addi\u00adents and is an indus\u00adtry leader in a full range of products for the treat\u00adment of respi\u00adra\u00adtory, inflamm\u00ada\u00adtory and liver dise\u00ada\u00adses driven by life\u00adstyle chan\u00adges. Many of the company\u2019s products require special treat\u00adment proces\u00adses and\/or tech\u00adno\u00adlo\u00adgies. Phar\u00adma\u00adZell, head\u00adquar\u00adte\u00adred in Raub\u00adling (near Munich), opera\u00adtes four state-of-the-art produc\u00adtion and R&amp;D sites in Germany, Italy and India and employs over 900 people worldwide.<\/p>\n<p>Bridge\u00adpoint mana\u00adges more than \u20ac29 billion in assets provi\u00added by global inves\u00adtors. These include public and private pension funds, asset mana\u00adgers, family offices, inde\u00adpen\u00addent autho\u00adri\u00adties and insu\u00adrance compa\u00adnies around the&nbsp;world.<\/p>\n<p><strong>Advi\u00adsors Phar\u00adma\u00adZell: P+P P\u00f6llath + Part\u00adners<\/strong> advi\u00adsed the manage\u00adment around CEO Oliver Bolzern.<br>\nDr. Bene\u00addikt Hohaus (Part\u00adner, Lead Part\u00adner, MPP, M&amp;A\/Private Equity)<br>\nDr. Roman Sten\u00adzel (Coun\u00adsel, MPP, M&amp;A\/Private Equity)<br>\nSilke Bande\u00adner (Asso\u00adciate, MPP, M&amp;A\/Private Equity, all Munich)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Munich \u2014 Inter\u00adna\u00adtio\u00adnal private equity inves\u00adtor Bridge\u00adpoint acqui\u00adres a majo\u00adrity stake in Phar\u00adma\u00adZell from DPE Deut\u00adsche Private Equity and Maxburg Capi\u00adtal Part\u00adners. The parties have agreed not to disc\u00adlose the purchase price. Phar\u00adma\u00adZell is a leading inde\u00adpen\u00addent manu\u00adfac\u00adtu\u00adrer of Active Phar\u00admaceu\u00adti\u00adcal Ingre\u00addi\u00adents (API) in the highly stable and specia\u00adli\u00adzed API market. There, the company has&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":43151,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1365,1366],"tags":[],"class_list":["post-43142","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-private-equity-en","category-news-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Secondary: Bridgepoint acquires majority stake in PharmaZell - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Secondary: Bridgepoint acquires majority stake in PharmaZell - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Munich \u2014 Inter\u00adna\u00adtio\u00adnal private equity inves\u00adtor Bridge\u00adpoint acqui\u00adres a majo\u00adrity stake in Phar\u00adma\u00adZell from DPE Deut\u00adsche Private Equity and Maxburg Capi\u00adtal Part\u00adners. The parties have agreed not to disc\u00adlose the purchase price. Phar\u00adma\u00adZell is a leading inde\u00adpen\u00addent manu\u00adfac\u00adtu\u00adrer of Active Phar\u00admaceu\u00adti\u00adcal Ingre\u00addi\u00adents (API) in the highly stable and specia\u00adli\u00adzed API market. There, the company has [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2020-02-20T11:56:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/02\/a-bridge.png\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Secondary: Bridgepoint acquires majority stake in PharmaZell\",\"datePublished\":\"2020-02-20T11:56:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/\"},\"wordCount\":209,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/02\/a-bridge.png\",\"articleSection\":[\"General\",\"Featured\",\"Private equity\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/\",\"url\":\"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/\",\"name\":\"Secondary: Bridgepoint acquires majority stake in PharmaZell - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/02\/a-bridge.png\",\"datePublished\":\"2020-02-20T11:56:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/02\/a-bridge.png\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/02\/a-bridge.png\",\"width\":200,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Secondary: Bridgepoint acquires majority stake in PharmaZell\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Secondary: Bridgepoint acquires majority stake in PharmaZell - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/","og_locale":"en_US","og_type":"article","og_title":"Secondary: Bridgepoint acquires majority stake in PharmaZell - FYB Financial Yearbook","og_description":"Munich \u2014 Inter\u00adna\u00adtio\u00adnal private equity inves\u00adtor Bridge\u00adpoint acqui\u00adres a majo\u00adrity stake in Phar\u00adma\u00adZell from DPE Deut\u00adsche Private Equity and Maxburg Capi\u00adtal Part\u00adners. The parties have agreed not to disc\u00adlose the purchase price. Phar\u00adma\u00adZell is a leading inde\u00adpen\u00addent manu\u00adfac\u00adtu\u00adrer of Active Phar\u00admaceu\u00adti\u00adcal Ingre\u00addi\u00adents (API) in the highly stable and specia\u00adli\u00adzed API market. There, the company has [&hellip;]","og_url":"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2020-02-20T11:56:52+00:00","og_image":[{"width":200,"height":200,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/02\/a-bridge.png","type":"image\/png"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Secondary: Bridgepoint acquires majority stake in PharmaZell","datePublished":"2020-02-20T11:56:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/"},"wordCount":209,"commentCount":0,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/02\/a-bridge.png","articleSection":["General","Featured","Private equity","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/","url":"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/","name":"Secondary: Bridgepoint acquires majority stake in PharmaZell - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/02\/a-bridge.png","datePublished":"2020-02-20T11:56:52+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/02\/a-bridge.png","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/02\/a-bridge.png","width":200,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/secondary-bridgepoint-acquires-majority-stake-in-pharmazell\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Secondary: Bridgepoint acquires majority stake in PharmaZell"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=43142"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43142\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/43151"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=43142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=43142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=43142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}